Magenta Therapeutics - MGTA Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares.
View MGTA analyst ratings or view top-rated stocks.

5 analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their MGTA share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 837.7% from the stock's current price.
View analysts price targets for MGTA or view top-rated stocks among Wall Street analysts.

Magenta Therapeutics' stock was trading at $0.3950 at the beginning of the year. Since then, MGTA stock has increased by 17.0% and is now trading at $0.4621.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our MGTA earnings forecast.

Magenta Therapeutics, Inc. (NASDAQ:MGTA) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04.

3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hellman Jordan Management Co. Inc. MA (0.73%). Insiders that own company stock include Bruce Booth and Kristen Stants.
View institutional ownership trends.

Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGTA stock can currently be purchased for approximately $0.46.

Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $27.98 million. The company earns $-71,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 242-0170 or via email at investor@magentatx.com.